Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Medicinova

Clinical trials sponsored by Medicinova, explained in plain language.

MediciNova MNOV NASDAQ

A biopharmaceutical company developing treatments for neurological and inflammatory diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 2 Completed 1

New drug MN-001 tested for scarred lungs in tiny trial

Disease control Completed

This study tested an experimental drug called MN-001 (tipelukast) in 15 people with moderate to severe idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Participants took either the drug or a placebo twice daily for six months, then everyone could take the drug for an…

Phase: PHASE2 • Sponsor: MediciNova • Aim: Disease control

Last updated Jun 27, 2026 08:13 UTC